Q3 2025 CVRx Inc Earnings Call Transcript

Nov 5, 2025 / 09:30 PM GMT

Release Date Price: $9.79 (-2.00%)

Transcript 10-Q8-K

Key Points

Positve

CVRx Inc (CVRX) reported a strong Q3 with double-digit year-over-year revenue growth and an expanded commercial footprint.
The company successfully onboarded new sales reps, contributing to increased procedure volumes and productive relationships with physicians.
CVRx Inc (CVRX) added 10 net new centers this quarter, with top accounts demonstrating deepening adoption of Barostim therapy.
The transition to a Category 1 CPT code effective January 1, 2026, is expected to improve reimbursement processes and patient access.
Gross margin increased to 87% in Q3 2025, driven by higher average selling prices and improved manufacturing efficiencies.

Negative

Despite revenue growth, CVRx Inc (CVRX) reported a net loss of $12.9 million for Q3 2025.
Revenue growth in Europe was modest, with a decrease in total revenue units compared to the prior year.
R&D expenses increased by 26% due to higher compensation and consulting expenses.
The company is still working on improving the productivity of new sales reps, which can take 6 to 12 months.
The guidance for Q4 2025 implies flat year-over-year growth, indicating potential conservatism or challenges in achieving higher growth rates.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CVRX.OQ - CVRx Inc
Q3 2025 CVRx Inc Earnings Call
Nov 05, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the CVRX 3rd quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Valley from ICR Healthcare.

Thank you, sir. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon.

Thank you for joining us today for CBRX's 3rd

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.